January 7, 2015 | An Israeli biopharmaceutical company, cCAM Biotherapeutics, announced that it received Food & Drug Administration approval to begin a Phase I trial for CM-24. CM-24 is a antibody for the treatment of various types of cancers. cCAM was founded in 2010 and focuses on the discovery and development of novel immunotherapies to treat cancer. The CM-24 antibody was discovered by Dr. Gal Markel, Head of Research in the Ella Institute of Melanoma at Sheba Academic Medical Center.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
UK Adopts Israeli Counter-Drone Technology
April 25, 2024
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments